FDA OKs new clinical trial for EnteroMedics anti-obesity device

Let’s do it again.EnteroMedics Inc., based in Roseville, Minnesota, said Monday that the Food and Drug Administration has approved a new clinical trial for its Maestro anti-obesity device that uses electricity to suppress hunger.The news represents a major victory for EnteroMedics whose previous study ended in failure. Last October, initial results from the EMPOWER studies [...]

[Read more of this report]


EnteroMedics retools, refocuses to win FDA approval

Someday, in the not-so-distant future, EnteroMedics Inc. officials might look back at late 2009 and laugh. Or cry.That ultimately depends on whether the Food and Drug Administration ultimately approves or rejects the company’s groundbreaking Maestro device. Approval means enormous financial success, the only implantable neurostimulation device in the United States designed to treat obesity. Rejection [...]

[Read more of this report]


EnteroMedics CEO: Don’t lump us in with failed Leptos Biomedical

EnteroMedics and Leptos are both developing a device that uses electricity to treat obesity. But that’s where the similarities end, EnteroMedics CEO Mark Knudson told me in a quick phone call.

[Read more of this report]


EnteroMedics Inc.’s fate now in the hands of the FDA. Your guess is as good as mine.

EnteroMedics is dangling precariously off a cliff. Last fall, initial results from its Empower clinical study failed to meet the company’s goals.

[Read more of this report]


Be a Thought Leader: Join MedCitizens

Anyone can blog on MedCity News when they become a "MedCitizen." MedCitizens publish their own thoughts about current medical news and the latest issues in healthcare to the entire MedCity News audience.

Click to login or learn more

MedCity Twitter Buzz

MedCity Jobs Board

Real Time Web Analytics